

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicants:</b>	Michel Xilinas et al.	<b>Examiner:</b>	Kendra D. Carter
<b>Serial No.:</b>	10/717,182	<b>Art Unit:</b>	1617
<b>Filed:</b>	November 18, 2003	<b>Docket:</b>	18381A
<b>For:</b>	USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE	<b>Dated:</b>	March 17, 2009

**Confirmation No.:** 5994

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE UNDER 37 C.F.R. § 1.111**

Sir:


In response to the Office Action dated November 17, 2008, Applicants submit the following amendment for entry in the above-identified application. The Amendment to the Specification commences on page 2 hereof, the Amendment to the Claims commence on page 3 hereof, and the Remarks section commences on page 6 of this Response.

---

**CERTIFICATION OF ELECTRONIC FILING**

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website, on March 17, 2009.

Dated: March 17, 2009

  
\_\_\_\_\_  
Mark J. Cohen